AB1200 Cognitive impairment associated with S100β protein in childhood-onset systemic lupus erythematosus. (23rd January 2014)

• Record Type: Journal Article
• Authors: Aldar, H.; Lapa, A.T.; Belini, B.; Sinicato, N.A.; Postal, M.; Fernandes, P.; Marini, R.; Appenzeller, S.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 706
• Page End: 706
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.1198
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: To determine clinical and laboratorial manifestations associated with S100β protein in childhood-onset systemic lupus erythematosus (cSLE) patients Methods: We included consecutive cSLE patients with disease onset before the age of 16 and healthy controls and age and healthy age and sex matched controls. All subjects underwent a standardized neuropsychological evaluation assessing the following: simple attention, complex attention, memory, visuospatial processing, language, reasoning/problem solving, psychomotor speed, and executive functions. Individual results were converted into standard scores and compared to normative data. Subjects with a total score in any of the 8 domains ≤-2 SD below the normative value were considered impaired. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory (BDI and BAI) in all subjects. cSLE patients were assessed for disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. S100β protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Clinical/laboratorial manifestations, disease activity, cumulative damage and drugs undertaken were assessed at time of blood withdrawal. Results: We included 42 cSLE patients (mean age 16.56±3.68) and 20 healthy controls (mean age 19.9±5.31). Cognitive impairment was observed in 25 (60%) cSLE patients and in 3 (15%) healthy controls (p<0.05). Patients with cognitive impairment presented significantly higher levels of the S100β protein (median 38.64) compared to patients without cognitive impairment (median 25.49; p=0.001) and controls (median 23.62; p<0.001). No other clinical/laboratorial manifestations and drugs undertaken were associated to S100β protein levels in cSLE. Conclusions: Cognitive impairment was associated with higher levels of the S100β protein, suggesting the presence of neuronal lesions in this cSLE patients cohort. Disclosure of Interest: H. Aldar Grant/Research support from: FAPESP 2009/13046-3, A. Lapa Grant/Research support from: FAPESP 2010/13639-1, B. Belini Grant/Research support from: FAPSEP 2009/12343-4, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, M. Postal Grant/Research support from: FAPESP 2009/11076-2, P. Fernandes: None Declared, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)